Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Biton

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Bioorganic & Medicinal Chemistry|January 13, 2000
Microbial models of drug metabolism: microbial transformations of Trimegestone (RU27987), a 3-keto-delta(4,9(10))-19-norsteroid drugI Lacroix, J Biton, R Azerad
Bioorganic & Medicinal Chemistry|July 1, 1997
Microbial biotransformations of a synthetic immunomodulating agent, HR325I Lacroix, J Biton, R Azerad
Biotechnology and Bioengineering|April 20, 1995
Enzymatic glucosylation of hydrophobic alcohols in organic medium by the reverse hydrolysis reaction using almond-beta-D-glucosidaseG Vic, J Biton, D Le Beller, et al.
Annals of the New York Academy of Sciences|March 31, 1995
Enzymatic synthesis of low-calorie sugar substitutes. Cellobiofructose and gentiobiofructoseJ Biton, J M Michel, D Le Beller, et al.
Cytokine|July 16, 2014
Interleukin-35 gene therapy exacerbates experimental rheumatoid arthritis in miceA Thiolat, A Denys, M Petit, et al.
Revue De Pneumologie Clinique|October 20, 2018
[Biomarkers predictive of PD1/PD-L1 immunotherapy in non-small cell lung cancer]A Lupo, M Alifano, M Wislez, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|June 4, 2014
Reply: To PMID 24504799A Thiolat, J Biton, P Decker, et al.
Clinical and Experimental Immunology|March 14, 2013
Protection from articular damage by passive or active anti-tumour necrosis factor (TNF)-α immunotherapy in human TNF-α transgenic mice depends on anti-TNF-α antibody levelsL Semerano, J Biton, L Delavallée, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|February 8, 2014
Interleukin-6 receptor blockade enhances CD39+ regulatory T cell development in rheumatoid arthritis and in experimental arthritisA Thiolat, L Semerano, Y M Pers, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Bioorganic & Medicinal Chemistry|January 13, 2000
Microbial models of drug metabolism: microbial transformations of Trimegestone (RU27987), a 3-keto-delta(4,9(10))-19-norsteroid drugI Lacroix, J Biton, R Azerad
Bioorganic & Medicinal Chemistry|July 1, 1997
Microbial biotransformations of a synthetic immunomodulating agent, HR325I Lacroix, J Biton, R Azerad
Biotechnology and Bioengineering|April 20, 1995
Enzymatic glucosylation of hydrophobic alcohols in organic medium by the reverse hydrolysis reaction using almond-beta-D-glucosidaseG Vic, J Biton, D Le Beller, et al.
Annals of the New York Academy of Sciences|March 31, 1995
Enzymatic synthesis of low-calorie sugar substitutes. Cellobiofructose and gentiobiofructoseJ Biton, J M Michel, D Le Beller, et al.
Cytokine|July 16, 2014
Interleukin-35 gene therapy exacerbates experimental rheumatoid arthritis in miceA Thiolat, A Denys, M Petit, et al.
Revue De Pneumologie Clinique|October 20, 2018
[Biomarkers predictive of PD1/PD-L1 immunotherapy in non-small cell lung cancer]A Lupo, M Alifano, M Wislez, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|June 4, 2014
Reply: To PMID 24504799A Thiolat, J Biton, P Decker, et al.
Clinical and Experimental Immunology|March 14, 2013
Protection from articular damage by passive or active anti-tumour necrosis factor (TNF)-α immunotherapy in human TNF-α transgenic mice depends on anti-TNF-α antibody levelsL Semerano, J Biton, L Delavallée, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|February 8, 2014
Interleukin-6 receptor blockade enhances CD39+ regulatory T cell development in rheumatoid arthritis and in experimental arthritisA Thiolat, L Semerano, Y M Pers, et al.
Pageof 1